Myogen, a University of Colorado Medical Center-based company, developed therapeutics for the treatment of heart disease. The company's strategy was to leverage its molecular and clinical expertise in heart muscle disease to discover new therapeutic targets for drug development, and develop and add value to in-licensed products. Myogen had an initial public offering in 2003, then was acquired by Gilead Pharmaceuticals in 2006.